Select a Country Careers Partnerships Investors Newsroom
Careers Abbvie Experience Student Opportunities
PARTNERSHIPS LICENSING AREAS OF INTEREST PROCESS OVERVIEW submit opportunity
INVESTORS INVESTOR RESOURCES REPORTS & FINANCIALS STOCK Information EVENTS & PRESENTATIONS Corporate Governance
newsroom latest news media contacts
ABOUT US Research & Innovation PRODUCTS RESPONSIBILITY
ABOUT US WHO WE ARE LEADERSHIP Board of Directors Board Committees ETHICS & compliance fact sheets
RESEARCH & INNOVATION FOCUS AREAS PIPELINE Research & DEVELOPMENT CLINICAL TRIALS CONDUCT & TRANSPARENCY Postmarketing Commitments Clinical Study Results
Products MATERIAL SAFETY DATA SHEETS  
RESPONSIBILITY Letter from the CEO PATIENTS FIRST Patient Assistance Programs Global Product Protection INNOVATION Improving Global Health Responsible Research Collaboration Sustainable Approaches to Health Care CREATING A CULTURE OF RESPONSIBILITY Environmental Stewardship Transparency Community Involvement Suppliers Supply Chain Management POLICIES & DISCLOSURES Corporate Political Participation

Research and Innovation > Pipeline

Pipeline

We're tackling diseases where there is a significant patient need for more and better solutions, with our focus on hepatitis C, multiple sclerosis, Alzheimer's disease, chronic pain, cancer, and more. Our scientists are working to advance a pipeline of specialty medicines that demonstrate both strong clinical performance and economic value. Our expertise in both small molecules and biologics gives us the flexibility to find and pursue the best solution for a given disease.

Development by Therapeutic Area


Our expertise in both small molecules and biologics allows us to find and pursue the best solution for a given disease.

Therapeutic Area Phase II Phase III/Submitted
Antiviral
(Hepatitis C)		   HCV Interferon-Free
Combination (genotype 1)
Immunology BT-061
Rheumatoid Arthritis
Psoriasis

GLPG0634
Rheumatoid Arthritis 		HUMIRA (adalimumab)
Hidradenitis Suppurativa
Axial Spondyloarthritis (U.S.)
Peripheral Spondyloarthritis
Uveitis
Pediatric Crohn's Disease (U.S.)
Neuroscience ABT-126
Alzheimer's Disease
Cognitive Deficits of
Schizophrenia		 Daclizumab
Relapsing Remitting Multiple
Sclerosis

Levodopa/Carbidopa
Intestinal Gel (LCIG)
Advanced Parkinson's Disease
Oncology Veliparib
BRCA-Deficient Breast Cancer
Other Cancers		 Elotuzumab
Multiple Myeloma
Women's Health Elagolix
Uterine Fibroids		 Elagolix
Endometriosis
Renal Disease ABT-719
Acute Kidney Injury

Atrasentan
Diabetic Nephropathy		  

Pipeline Highlights

10

Programs in Phase III Underway

30%

Approximate Percentage of Pipeline Focus on Biologics

9

New Molecules From External Sources in Pipeline Since 2010

15

Major Regulatory Submissions Planned : 2013 - 2017

ABOUT US research and Innovation PRODUCTS responsibility
Careers Partnership Investors Newsroom

A pioneering spirit. A collaborative nature. And the resources and skill to bring improved quality of life to market.

For more information
Contact Us »

Site map | Privacy policy | Terms of use
Copyright © 2013 AbbVie Inc. North Chicago, Illinois, U.S.A.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

ABBVIE:
A Global Company

Our passion lies in developing advanced therapies to address the world’s most difficult health problems.

Select a Country »

Follow US for: news   careers

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?